Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

WolverineBlend_20MG

Wolverine Blend

Wolverine Blend is a research-grade peptide formulation combining two well-characterized synthetic peptides: BPC-157 and Thymosin Beta-4 (TB-500). This blend is designed for laboratory and experimental research applications focused on peptide-mediated cellular signaling, tissue repair mechanisms, angiogenic pathways, and cytoskeletal dynamics.*

Both peptides included in Wolverine Blend have been extensively referenced in scientific literature for their individual roles in cellular migration, vascular signaling, extracellular matrix interactions, and tissue regeneration models. When studied together, they provide a complementary research platform for investigating coordinated peptide activity across multiple biological systems.*

  • Product Name: Wolverine Blend
  • Peptide Components:
    • 10mg BPC-157 (Body Protection Compound-157)
    • 10mg Thymosin Beta-4 (TB-500)
  • Peptide Class: Synthetic regenerative research peptides
  • Form: Lyophilized powder
  • Purity: ≥99% (each peptide, HPLC verified)
  • Total Quantity: 20 mg per vial
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Solid-phase peptide synthesis with in-house purification
  • Designation: For Research Use Only (RUO)

$116.00

$110.20 each
$104.40 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

Wolverine Blend

Scientific & Research Context

BPC-157 is a synthetic pentadecapeptide originally identified as a stable gastric peptide fragment. In research settings, it has been widely studied for its involvement in angiogenic signaling, nitric oxide modulation, cytoprotection, and tissue repair mechanisms across gastrointestinal, musculoskeletal, vascular, and neural experimental models.*

Thymosin Beta-4 (TB-500) is a synthetic analog of a naturally occurring actin-binding peptide involved in cytoskeletal organization, cell migration, and angiogenesis. TB-500 is frequently utilized in research examining wound healing, stem cell mobilization, vascular development, and inflammatory modulation.*

When combined in Wolverine Blend, these peptides are commonly explored in experimental systems to evaluate:*

• Peptide-driven tissue repair and regeneration pathways
• Angiogenesis and vascular remodeling signaling
• Cell migration, proliferation, and cytoskeletal dynamics
• Extracellular matrix interactions and wound healing models
• Coordinated effects of multi-peptide signaling systems

This blend offers researchers a consolidated platform for studying synergistic peptide activity in controlled in-vitro and preclinical research environments.*

Quality & Analytical Assurance

Each batch of Wolverine Blend undergoes comprehensive analytical testing to verify peptide identity, purity, and molecular integrity. Independent HPLC and mass spectrometry analyses ensure consistent peptide composition, reproducibility, and reliability across research applications.

Strict quality control standards are maintained throughout synthesis, purification, and packaging to support high-confidence experimental outcomes.

Storage & Handling

Wolverine Blend is supplied in lyophilized form to maximize stability during storage and transport. Unopened vials should be stored in a cool, dry environment and protected from light. Reconstitution and handling should follow standard peptide research protocols and laboratory best practices to preserve peptide stability and biological integrity.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • T. Huang et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Design, Development and Therapy, vol. 9, pp. 2485–2499, 2015.
  • D. Drmić et al., “Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC-157, L-NAME and L-arginine,” World Journal of Gastroenterology, vol. 24, no. 48, pp. 5462–5476, 2018.
  • F. Amić et al., “Bypassing major venous occlusion and duodenal lesions in rats and therapy with stable gastric pentadecapeptide BPC-157,” World Journal of Gastroenterology, vol. 24, no. 47, pp. 5366–5378, 2018.
  • A. Duželj et al., “Stable gastric pentadecapeptide BPC-157 in the treatment of colitis and ischemia-reperfusion in rats,” World Journal of Gastroenterology, vol. 23, no. 48, pp. 8465–8488, 2017.
  • J. Vukojević et al., “Inferior caval vein ligature and vascular recruitment mediated by BPC-157,” Vascular Pharmacology, vol. 106, pp. 54–66, 2018.
  • D. Drmić et al., “Celecoxib-induced gastrointestinal, liver and brain lesions counteracted by BPC-157,” World Journal of Gastroenterology, vol. 23, no. 29, pp. 5304–5312, 2017.
  • M.-J. Hsieh et al., “Therapeutic potential of pro-angiogenic BPC-157 is associated with VEGFR2 activation,” Journal of Molecular Medicine, vol. 95, no. 3, pp. 323–333, 2017.
  • Z. Grabarević et al., “Influence of BPC-157 on nitric oxide agonist- and antagonist-induced lesions,” Journal of Physiology (Paris), vol. 91, no. 3–5, pp. 139–149, 1997.
  • P. Šikirić et al., “Novel cytoprotective mediator BPC-157: vascular recruitment and gastrointestinal tract healing,” Current Pharmaceutical Design, vol. 24, no. 18, pp. 1990–2001, 2018.
  • S. Seiwerth et al., “BPC-157 and standard angiogenic growth factors: lessons from tendon, ligament, muscle and bone healing,” Current Pharmaceutical Design, vol. 24, no. 18, pp. 1972–1989, 2018.
  • C.-H. Chang, W.-C. Tsai, M.-S. Lin, Y.-H. Hsu, and J.-H. S. Pang, “The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” Journal of Applied Physiology, vol. 110, no. 3, pp. 774–780, 2010.
  • C.-H. Chang, W.-C. Tsai, Y.-H. Hsu, and J.-H. S. Pang, “Pentadecapeptide BPC-157 enhances growth hormone receptor expression in tendon fibroblasts,” Molecules, vol. 19, no. 11, pp. 19066–19077, 2014.
  • P. Cheng et al., “Beneficial effects of thymosin β4 on spinal cord injury in the rat,” Neuropharmacology, vol. 85, pp. 408–416, 2014.
  • M. Chopp and Z. G. Zhang, “Thymosin β4 as a restorative/regenerative therapy for neurological injury and neurodegenerative diseases,” Expert Opinion on Biological Therapy, vol. 15 Suppl 1, pp. S9–S12, 2015.
  • H. Li et al., “Thymosin beta-4 attenuates oxidative stress-induced injury of neural stem/progenitor cells,” Gene, vol. 707, pp. 136–142, 2019.
  • K. N. Dubé and N. Smart, “Thymosin β4 and the vasculature: multiple roles in development, repair, and protection,” Expert Opinion on Biological Therapy, vol. 18, no. sup1, pp. 131–139, 2018.
  • D. Philp et al., “Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development,” Mechanisms of Ageing and Development, vol. 125, no. 2, pp. 113–115, 2004.
  • J. Kim and Y. Jung, “Potential role of thymosin beta-4 in liver fibrosis,” International Journal of Molecular Sciences, vol. 16, no. 5, pp. 10624–10635, 2015.
  • R. Song et al., “Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy,” Clinical Rheumatology, vol. 31, pp. 1253–1258, 2012.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.